Table 2. Multivariate Analysis for Relapse, Leukemia-Free Survival, and Overall Survival.
| Variable | Relapse | Leukemia-free survival | Overall survival | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, ≥37 y vs <37 y | 1.02 (0.71-1.45) | .89 | 1.02 (0.71-1.47) | .93 | 1.19 (0.84-1.68) | .33 |
| Sex, female vs male | 1.04 (0.73-1.46) | .85 | 1.12 (0.79-1.58) | .65 | 1.09 (0.79-1.51) | .59 |
| WBC count, ≥20 000/µL vs <20 000/µL | 1.33 (0.93-1.90) | .12 | 1.27 (1.00-1.79) | .18 | 1.20 (0.86-1.66) | .29 |
| Cycles to achieve CR, 2 vs 1 | 1.81 (1.19-2.76) | .006 | 1.97 (1.33-2.90) | .001 | 1.78 (1.23-2.58) | .002 |
| MRD1 | 1.24 (0.44-3.56) | .68 | 1.11 (0.42-3.04) | .81 | 1.35 (0.48-3.78) | .57 |
| MRD2 | 1.47 (0.92-2.36) | .19 | 1.49 (0.95-2.33) | .19 | 1.32 (0.86-2.02) | .28 |
| MRD3 | 3.93 (1.55-9.97) | .004 | 3.93 (1.65-9.37) | .002 | 6.21 (2.47-15.63) | <.001 |
| PRT | ||||||
| Auto-SCT vs CMT | 0.49 (0.31-0.78) | .002 | 0.50 (0.32-0.79) | .003 | 0.60 (0.38-0.94) | .03 |
| Allo-SCT vs CMT | 0.12 (0.08-0.19) | <.001 | 0.12 (0.08-0.19) | <.001 | 0.33 (0.23-0.48) | <.001 |
| Allo-SCT vs auto-SCT | 0.25 (0.16-0.41) | <.001 | 0.24 (0.15-0.39) | <.001 | 0.56 (0.36-0.88) | .01 |
Abbreviations: allo-SCT, allogeneic stem cell transplant; auto-SCT, autologous stem cell transplant; CMT, chemotherapy; CR, complete remission; HR, hazard ratio; MRD1, measurable residual disease after 1 course of CMT; MRD2, measurable residual disease after 2 courses of CMT; MRD3, measurable residual disease after 3 courses of CMT; PRT, postremission treatment; WBC, white blood cell.